Compare S&P500 ETF (SPY) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
S&P500 ETF vs BIO-TECHNE Corp — how do they compare? S&P500 ETF trades at $778.23 (market cap $821.54B), while BIO-TECHNE Corp trades at $72.45 (market cap $11.36B). The key difference: S&P500 ETF is far larger — about 72.3× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while S&P500 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold S&P500 ETF for 205 Days and BIO-TECHNE Corp for 63 Days on average.
| SPY | TECH | |
|---|---|---|
Market Cap | $821.54B | $11.36B |
Volume | 40,070,358 | 5,390,331 |
52-Week High | $779.14 | $72.61 |
52-Week Low | $631.99 | $43.31 |
Typical Hold Time | 205 Days | 63 Days |
Sector | — | Health |
Enterprise Value | — | $11.39B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPY (SPDR S&P 500 ETF Trust) trades at $778.18, up 0.12% with a bullish technical signal from moving averages. The ETF shows neutral oscillator readings with RSI at 68.54 suggesting mild overbought conditions. Recent news highlights S&P 500 valuation debates and profit growth expectations of 35% for 2026. Technical support sits at $771 with resistance at $777.
Outlook remains cautiously optimistic given the ETF's broad market exposure, though risks include potential profit growth deceleration to 15% in 2027 and market-wide valuation concerns. The dividend yield of approximately 0.24% provides modest income, while institutional positioning favors large-cap stability amid economic uncertainty.
Bio-Techne (TECH) trades at $72.45, down 0.11% on the day, near its 52-week high of $72.70. The stock shows bullish technical signals with strong moving average support. Fundamentally, the company maintains solid gross margins of 65.77% but faces declining net income margins, dropping from 24.6% in 2022 to 6.01% in 2025. Recent shareholder approval of Merck KGaA's acquisition at $73 per share provides a clear near-term catalyst.
The pending acquisition offers limited upside from current levels but provides downside protection. However, declining profitability trends and elevated valuation ratios (P/E 62.46) pose risks if the deal falls through. Investors should weigh the acquisition premium against fundamental deterioration in earnings quality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About S&P500 ETF
The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on SPY →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
